Intervention/Treatment: The trial tests Itepekimab, administered subcutaneously in high and low doses, alongside Mometasone furoate nasal spray. The purpose is to improve symptoms in patients with ...

Itepekimab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement and is currently in clinical development programs for CRSwNP (phase 3), non-cystic fibrosis ...

Itepekimab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement and is currently in clinical development programs for chronic rhinosinusitis with nasal polyps ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) on Friday announced results from two Phase 3 trials of itepekimab in chronic obstructive pulmonary disease (COPD) patients ...

About itepekimab In partnership with Regeneron, Sanofi is exploring itepekimab, a fully human monoclonal antibody that binds to and inhibits IL33, an initiator and amplifier of broad inflammation ...

The companies are currently assessing the data to decide next steps. Why it matters: This is a disappointing setback for itepekimab, a key pipeline asset for both Regeneron and Sanofi.

Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease non-cystic fibrosis bronchiectasis (NFCB).

Itepekimab is due for a readout in 2025, according to Naimish Patel, M.D., Sanofi’s head of global development, immunology and inflammation. The drug is an IL-33 inhibitor, while Dupixent ...

AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a ...

About itepekimab In partnership with Regeneron, Sanofi is exploring itepekimab, a fully human monoclonal antibody that binds to and inhibits IL33, an initiator and amplifier of broad inflammation ...